

\$4.9+ Billion Allergy Immunotherapy Market by 2033 with a 10.4% CAGR – Allied Market Research

PORTLAND, OR, UNITED STATES,
November 21, 2024 /

EINPresswire.com/ -- Increase in prevalence of allergies and rise in focus on personalized medicine are the major factors that drive the global market growth.

Allied Market Research published a report, titled, "[Allergy Immunotherapy Market](#) by Type (Subcutaneous Immunotherapy and Sublingual Immunotherapy), Application (Allergy Rhinitis, Asthma, Food Allergy and Others), and Distribution Channel (Hospital Pharmacies, Retail and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2024-2033".

According to the report, the allergy immunotherapy market was valued at \$1.8 billion in 2023, and is estimated to reach \$4.9 billion by 2033, growing at a CAGR of 10.4% from 2024 to 2033.



Request a sample: <https://www.alliedmarketresearch.com/request-sample/A10241>

Prime determinants of growth

Rise in prevalence of allergy cases and surge in focus on personalized medicine are the major factors that drive the growth of the allergy immunotherapy market. However, the risk of side effects hinders market growth. Moreover, increase in focus on advancements in immunotherapy treatments offer remunerative opportunities for the expansion of the global allergy immunotherapy market.

Report coverage & details

Report Coverage

Details

Forecast Period

2024–2033

Base Year

2023

Market Size in 2023

\$1.8 billion

Market Size in 2033

\$4.9 billion

CAGR

10.4%

No. of Pages in Report

216

Segments Covered

Type, Application, Distribution Channel, and Region.

Drivers

Increase in prevalence of allergies

Rise in focus on personalized medicine

Opportunities

Advancements in immunotherapy treatments

Restraints

Risk of side effects

Segment Highlights

The subcutaneous immunotherapy (SCIT) segment held the highest market share in 2023.

By type Subcutaneous immunotherapy (SCIT) is widely accepted due to its proven efficacy in reducing allergy symptoms and long-term benefits. Administered via regular injections, SCIT gradually desensitizes the immune system to allergens, offering sustained relief even after treatment ends. Its established safety profile, backed by extensive clinical research, makes it a preferred choice among allergists for managing severe allergic conditions.

Prevalence of allergic rhinitis

The rise in the prevalence of allergic rhinitis significantly contributes to the allergy immunotherapy market growth. Increasing cases drive the demand for effective long-term treatments, such as immunotherapy, which offers sustained relief compared to symptomatic treatments, leading to greater adoption and market expansion.

Hospitals pharmacies the major distributors of Allergy immunotherapy

Hospital pharmacies play a crucial role in distributing allergy immunotherapy, ensuring patients receive proper treatment. They dispense allergen extracts, manage inventory, and provide expert guidance on administration. Their accessibility and expertise make them primary sources for patients undergoing allergy treatment, ensuring safe and effective therapy.

Regional Outlook

The allergy immunotherapy market varies significantly by region. In North America and Europe, high healthcare expenditure and advanced medical infrastructure drive market growth, supported by rising allergy prevalence and awareness. In Asia-Pacific, increasing healthcare investments and growing awareness about allergic conditions are expected to boost market demand, while Latin America and the Middle East are gradually adopting these therapies, supported by improving healthcare systems and increased focus on chronic diseases.

Players

Torii Pharmaceutical Co., Ltd.

Biomay AG

ALK-Abello A/S

Allergy Therapeutics

Allovate, LLC

HAL Allergy Group

Jubliant Pharma

Leti Pharma

Merck KGaA

Stallergenes Greer

The report provides a detailed analysis of these key players in the global Allergy immunotherapy market. These players have adopted different strategies such as expansion, product approval, clinical trials, product launch and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.

Recent Industry Development

In May 2024, ALK-Abelló A/S, a pharmaceutical company which specializes in the development and manufacturing of allergy immunotherapy products, announced the European regulatory filing for ITULAZAX (tree sublingual allergy immunotherapy (SLIT) tablet) in young children has been accepted for review by the relevant health authorities.

In October 2021, Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), announced that the company has entered into an exclusive partnership with Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, for the development of the first of its kind connected device and companion mobile app for patients undergoing Stallergenes Greer's AIT treatments with sublingual solutions.

□□□□□□ □□□□□□ □□□□□□: <https://www.alliedmarketresearch.com/purchase-enquiry/A10241>

David Correa

Allied Market Research

+1 800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/762508861>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.